Wheeler Bio, an Oklahoma City, OK-based biopharmaceutical contract development and manufacturing organization (CDMO), raided $35M in Series A-1 funding.
The round was led by Alloy Therapeutics and Echo Investment Capital, with participation from Mitsubishi Corporation (Americas), Germin8 Ventures, and Russell Westbrook Enterprises.
The company intends to use the funds to expand its partner base, team, and capabilities in order to accelerate the advancement of its partners’ therapies.
Led by CEO and President Patrick Lucy, Wheeler Bio is a CDMO providing a scientific platform, Modular CMC, for drug development by enabling the rapid advancement of antibody-based therapeutic candidates from discovery into human clinical trials while establishing a robust chemistry, manufacturing, and controls (CMC) package vital for regulatory filings and ongoing cGMP manufacturing.
This includes services like:
- manufacturability assessments.
- stable pool and clone development.
- process and analytical method development.
- process demonstration.
- technology transfer.
- cGMP manufacturing.
FinSMEs
20/03/2025